130 related articles for article (PubMed ID: 31780055)
1. Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer.
Jiang FN; Dai LJ; Yang SB; Wu YD; Liang YX; Yin XL; Zou CY; Zhong WD
Pathol Res Pract; 2020 Jan; 216(1):152732. PubMed ID: 31780055
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
3. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
7. FKBP9 promotes the malignant behavior of glioblastoma cells and confers resistance to endoplasmic reticulum stress inducers.
Xu H; Liu P; Yan Y; Fang K; Liang D; Hou X; Zhang X; Wu S; Ma J; Wang R; Li T; Piao H; Meng S
J Exp Clin Cancer Res; 2020 Feb; 39(1):44. PubMed ID: 32111229
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
9. Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.
Zhang H; Qi C; Wang A; Yao B; Li L; Wang Y; Xu Y
J Exp Clin Cancer Res; 2013 Oct; 32(1):77. PubMed ID: 24422979
[TBL] [Abstract][Full Text] [Related]
10. High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.
Zhang Z; Xie H; Zhu S; Chen X; Yu J; Shen T; Li X; Shang Z; Niu Y
Med Sci Monit; 2018 Nov; 24():8190-8197. PubMed ID: 30427826
[TBL] [Abstract][Full Text] [Related]
11. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
13. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
14. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
15. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.
Huang Y; Jiang G; Liang X; Lan Z; Su Z; Wu H; Weng J; Jiang X
Mol Med Rep; 2018 Oct; 18(4):3914-3922. PubMed ID: 30132530
[TBL] [Abstract][Full Text] [Related]
17. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication and functional annotations of Rad50 expression in patients with prostate cancer.
Xu WH; Wang J; Sheng HY; Qu YY; Wang HK; Zhu Y; Shi GH; Zhang HL; Ye DW
J Cell Biochem; 2020 Jun; 121(5-6):3124-3134. PubMed ID: 31886567
[TBL] [Abstract][Full Text] [Related]
19. Metabolic deregulation in prostate cancer.
Srihari S; Kwong R; Tran K; Simpson R; Tattam P; Smith E
Mol Omics; 2018 Oct; 14(5):320-329. PubMed ID: 30215656
[TBL] [Abstract][Full Text] [Related]
20. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
